Is Cystatin-C superior to creatinine in the early diagnosis of contrast-induced nephropathy: A potential new biomarker for an old complication

Journal of Postgraduate Medicine

Volumn 60, Issue 2, 2014, Pages 135-140

  Ebru, A E ^a   Kilic, A ^a   Korkmaz, F S ^a   Seker, R ^a   Sasmaz, H ^a,b   Demirtas, S ^a   Biyikli, Z ^a,c  

^a UFUK UNIVERSITY   (Turkey)

^b Ankara Yuksek Ihtisas Education and Training Hospital   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Acute kidney injury; contrast media; coronary angiography; cystatin C; mehran risk score

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; IOHEXOL; NITROGEN; UREA; BIOLOGICAL MARKER; CONTRAST MEDIUM;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTATIN C BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; AGED; ANGIOGRAPHY; BLOOD; CHEMICALLY INDUCED; EARLY DIAGNOSIS; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; RISK FACTOR; TIME;

ACUTE KIDNEY INJURY; ADULT; AGED; ANGIOGRAPHY; BIOLOGICAL MARKERS; CONTRAST MEDIA; CREATININE; CYSTATIN C; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TIME FACTORS;

EID: 84901467779     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.132317     Document Type: Article

References (30)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39: 930-6.
2. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51: 1419-28.
3. Solomon R, Deray G; Consensus Panel for CIN. How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations. Kidney Int Suppl 2006;100: S51-3.
4. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Metaanalysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148: 284-94.
5. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: Physiological principles. Intensive Care Med 2004;30: 33-7.
6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002;40: 221-6.
7. Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 2004;61: 98-102.
8. Filler G, Bkenkamp A, Hofmann W, Le Bricon T, Martnez-Br C, Grubb A. Cystatin C as a marker of GFR - history, indications, and future research. Clin Biochem 2005;38: 1-8.
9. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrm V, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994;40: 1921-6.
10. Tanaga K, Tarao K, Nakamura Y, Inoue T, Jo K, Ishikawa T, et al. Percutaneous coronary intervention causes increase of serum cystatin C concentration even in the patients with a low risk of contrast-induced nephropathy. Cardiovasc Interv Ther 2012;27: 168-73.
11. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44: 1393-9.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31-41.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1): S1-266.
14. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275: 1489-94.
15. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11: R31.
16. Dalton RN. Serum creatinine and glomerular filtration rate: Perception and reality. Clin Chem 2010;56: 687-9.
17. Filler G, Bkenkamp A, Hofmann W, Le Bricon T, Martnez-Br C, Grubb A. Cystatin C as a marker of GFR - history, indication and future research. Clin Biochem 2005;38: 1-8.
18. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, et al. Association between increases in urinary neutrophil gelatinaseassociated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006;105: 485-91.
19. Ishibashi Y, Yamauchi M, Musha H, Mikami T, Kawasaki K, Miyake F. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficency patients undergoing cardiac catheterization. Angiology 2010;61: 724-30.
20. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimates of renal function: Searching for a better measure of kidney function in diabetic patients. Clin Chem 2007;53: 480-8.
21. Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C and contrast-induced acute kidney injury. Circulation 2010;121: 2117-22.
22. Liu XL, Wang ZJ, Yang Q, Yu M, Shen H, Nie B, et al. Plasma neutrophil-gelatinase-associated lipocalin and cystatin C could early diagnose contrast-induced acute kidney injury in patients with renal insufficiency undergoing an elective percutaneous coronary intervention. Chin Med J (Engl) 2012;125: 1051-6.
23. Ribichini F, Gambaro G, Graziani MS, Pighi M, Peasrini G, Pasoli P, et al. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin Chem 2012;58: 458-64.
24. Alharazy SM, Kong N, Saidin R, Gafor AH, Maskon O, Mohd M, et al. Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease. Angiology 2013.
25. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Pawlak K, Mysliwiec M, et al. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values Kidney Blood Press Res 2007;30: 408-15.
26. Buitrago F, Calvo JI, Gmez-Jimnez C, Can L, Robles NR, Angulo E. Comparison and agreement of the Cockcroft-Gault and MDRD equations to estimate glomerular filtration rate in diagnosis of occult chronic kidney disease. Nefrologia 2008;28: 301-10.
27. Solomon R, Dauerman HL. Contrast induced acute kidney injury. Circulation 2010;122: 2451-5.
28. Patel K, King CA, Jovin IS. Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention. Cardiovasc Revasc Med 2011;12: 90-3.
29. Alioglu E, Saygi S, Turk U, Kirilmaz B, Tuzun N, Duman C, et al. N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C. Cardiovasc Ther 2013;31: 168-73.
30. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11: R31.